These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 369693)

  • 1. VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474).
    Chiuten DF; Bennett JM; Creech RH; Glick J; Falkson G; Brodovsky HS; Begg CB; Muggia FM; Carbone PP
    Cancer Treat Rep; 1979 Jan; 63(1):7-11. PubMed ID: 369693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative trial of two teniposide-based combination chemotherapy regimens for the treatment of advanced malignant lymphomas.
    O'Connell MJ; Anderson J; Merrill JM; Bennett JM; Glick JH; Berard CW; Neiman RS; Brodovsky HS
    Cancer Treat Rep; 1982 Dec; 66(12):2021-5. PubMed ID: 6814757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Use of preparation VM 26 (epipodophyllotoxin) for treating lymphomas in children and adults].
    Kondrat'eva NA; Gershanovich ML; Kondrat'ev VB; Lebedev VN; Vialushkin VIa
    Vopr Onkol; 1981; 27(4):82-7. PubMed ID: 7015693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy for patients with relapsed malignant lymphoma using methyl-GAG and teniposide (VM-26).
    Warrell RP; Straus DJ; Young CW
    Cancer Treat Rep; 1982 May; 66(5):1121-5. PubMed ID: 7044533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
    Radice PA; Bunn PA; Ihde DC
    Cancer Treat Rep; 1979 Aug; 63(8):1231-9. PubMed ID: 225026
    [No Abstract]   [Full Text] [Related]  

  • 6. Combination chemotherapy with VM-26, adriamycin bleomycin, and prednisone as a secondary treatment of malignant lymphoma.
    Goldhirsch A; Pirovino M; Sonntag RW; Tschopp L; Ryssel HJ; Brunner KW
    Cancer Treat Rep; 1980; 64(2-3):335-7. PubMed ID: 6157468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of maytansine in patients with advanced lymphomas: an Eastern Cooperative Oncology Group pilot study.
    Rosenthal S; Harris DT; Horton J; Glick JH
    Cancer Treat Rep; 1980; 64(10-11):1115-7. PubMed ID: 7459897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of VP-16-213 in malignant lymphoma and melanoma.
    Cecil JW; Quagliana JM; Coltman CA; Al-Sarraf M; Thigpen T; Groppe CW
    Cancer Treat Rep; 1978 May; 62(5):801-3. PubMed ID: 657164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of VM-26 in acute leukemia, neuroblastoma, and other refractory childhood malignancies: a report from the Children's Cancer Study Group.
    Bleyer WA; Krivit W; Chard RL; Hammond D
    Cancer Treat Rep; 1979 Jun; 63(6):977-81. PubMed ID: 380803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of teniposide (VM 26) in advanced non-Hodgkin's lymphoma, with emphasis on the treatment of elderly patients.
    Tirelli U; Carbone A; Crivellari D; Volpe R; Franchin G; Veronesi A; Galligioni E; Trovò M; Tumolo S; Grigoletto E
    Cancer; 1984 Aug; 54(3):393-6. PubMed ID: 6375853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose teniposide for refractory malignancies: a phase I study.
    de Vries EG; Mulder NH; Postmus PE; Vriesendorp R; Willemse PH; Sleijfer DT
    Cancer Treat Rep; 1986 May; 70(5):595-8. PubMed ID: 3708608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of piperazinedione in Hodgkin's disease, non-Hodgkin's lymphoma, and multiple myeloma: a Southwest Oncology Group study.
    Jones SE; Tucker WG; Haut A; Tranum BL; Vaughn C; Chase EM; Durie BG
    Cancer Treat Rep; 1977 Dec; 61(9):1617-21. PubMed ID: 340032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combination of adriamycin, VM 26, cyclophosphamide and prednisone in the treatment of hematosarcomas].
    Laurens A; Thevenot J; Charron D; Jorry F; Dumonchel P; Martola R
    Ann Med Interne (Paris); 1977 May; 128(5):493-6. PubMed ID: 334012
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of the use of teniposide and vincristine in combination chemotherapy for non-Hodgkin's lymphoma.
    Cancer Treat Rep; 1982 Jan; 66(1):49-55. PubMed ID: 7053265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II evaluation of VM-26 in patients with metastatic transitional cell carcinoma of the urinary tract: an Eastern Cooperative Oncology Group study.
    Qazi R; Elson P; Khandekar JD
    Cancer Treat Rep; 1982 Feb; 66(2):405-6. PubMed ID: 7055823
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II study of hexamethylmelamine in refractory Hodgkin's disease, other lymphomas, and chronic lymphocytic leukemia.
    Omura GA; Broun GO; Papps J; Birch R
    Cancer Treat Rep; 1981; 65(11-12):1027-9. PubMed ID: 6794907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epipodophyllotoxin VM-26 in the treatment of childhood neuroblastoma.
    Rivera G; Green A; Hayes A; Avery T; Pratt C
    Cancer Treat Rep; 1977 Oct; 61(7):1243-8. PubMed ID: 589594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of advanced refractory lymphomas with a combination of carmustine, bleomycin, teniposide, dexamethasone, and cisplatin (the BBVDD regimen). An ECOG pilot study.
    Spiers AS; Weens JH; Rowe JM; Smith TJ; Horton J; Gordon LI; Glick JH
    Am J Clin Oncol; 1991 Dec; 14(6):519-25. PubMed ID: 1720279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A phase II study of mitoxantrone in refractory and relapsed malignant lymphomas. Cooperative Study Group of Mitoxantrone in Malignant Lymphomas].
    Kimura I; Ohnoshi T; Ogawa M; Sampi K; Masaoka T; Yamada K; Ohta K; Kitani T; Kawagoe H; Shirakawa S
    Gan To Kagaku Ryoho; 1986 Sep; 13(9):2800-6. PubMed ID: 3753026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.